Antifungal Drugs in Pulmonary Mucormycosis

Summary

Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis

Timeline

Start

2025-01-10

Primary completion

2025-07-10

Completion

2026-12-31

Drugs

Indications